Mironid Limited: Mironid Announces Closing of £4.3 million $6.2 million Series A Financing.
Financing will be used to support programmes focused on degenerative kidney disease major inflammatory disease and cancer. Glasgow Scotland UK 20th June 2016 Mironid Ltd a leader in cell signalling directed drug development today announced the closing of ...
Read full article »
Mironid is a Scotland-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease.
Read more